To strengthen Europe’s vaccine readiness and responsiveness in times of pandemics, the European Vaccine Hub (EHV) was inaugurated in Siena. The initiative consists of key actions that will, amongst others, speed up vaccine development to less than four months from identifying a pathogen’s genomic sequence.
The Hub will bring together nationally funded vaccine research and development investments at the EU level.
The Hub will be made up of a consortium of leading European organisations in vaccine development and national pandemic preparedness programmes. Each will leverage their extensive expertise in vaccine discovery, development, clinical trials, and manufacturing.
The EVH project is funded by the Commission’s Health Emergency Preparedness and Response Authority (HERA) through the EU4Health programme with up to €102 million.
Key objectives and actions of the Hub
The Hub will revolutionise vaccine development through its agile, decentralized structure. It will organise collaborative research across Europe, as well as ensure sustainability and continued operation beyond initial funding. Ultimately, it will enhance Europe’s capability to protect its citizens and bolster its economy against global health threats.
The EVH will focus on several key actions, including:
- Speed up vaccine development to less than four months from identifying a pathogen’s genomic sequence.
- Initiate a prototype vaccine strategy utilizing cutting-edge platform technologies.
- Leverage resources from the public and private sectors.
- Drive preclinical studies, Phase I/II, and Controlled Human Infection Model (CHIM) trials.
- Provide seamless access to vaccine production facilities, clinical trial sites, analytical laboratories, technology transfers, and expanded production via industry partnerships.
